Master this deck with 20 terms through effective study methods.
Generated from text input
The AIMS scale is used to quantify symptoms of tardive dyskinesia. It is administered at baseline when starting a new antipsychotic and then every 3-6 months to monitor for any changes in symptoms.
If the AIMS score increases, it indicates worsening symptoms, prompting a switch to a different antipsychotic. If the score remains the same or decreases, it suggests that the current medication is not causing tardive dyskinesia.
Tardive dyskinesia can be treated with VMAT2 inhibitors such as valbenazine or deutetrabenazine.
Long-acting injectable antipsychotics can be administered intramuscularly for patients with poor compliance or those who prefer this route. They help ensure consistent medication delivery and can reduce the risk of relapse.
The length of oral overlap after the first injection of a long-acting antipsychotic varies by drug, but it is typically recommended to continue oral therapy for a period to ensure adequate medication levels.
Initiate antipsychotic treatment and titrate the dose every few days to reach a moderate therapeutic dose. During the first week, improvements in sleep, appetite, and reductions in agitation, hostility, anxiety, and aggression should be observed.
If 'cheeking' is suspected, it is advisable to use liquid formulations or orally disintegrating tablets (ODT) to ensure the medication is ingested.
Lorazepam can be used in combination with quick-acting antipsychotics for severely agitated patients to help calm them. However, caution is needed when combining lorazepam with olanzapine due to the risk of hypotension and respiratory depression.
Optimal improvement typically takes 6 or more weeks. In the first 2-3 weeks, patients should show increased socialization, improved mood, and decreased hallucinations, while formal thought processes may take 6-8 weeks to improve.
Continued treatment is recommended for at least 5 years to prevent future relapse in patients with schizophrenia.
For a first psychotic episode, aripiprazole, risperidone, and ziprasidone are recommended as first-line treatments. If these are not effective, other first or second-generation antipsychotics that are not clozapine may be considered.
Treatment resistance is defined as the failure to respond to two or more antipsychotic medications. In such cases, clozapine is recommended, especially if the patient exhibits violent behaviors or suicidality.
The DSM-5 criteria for schizophrenia include the presence of 2 or more of the following symptoms for at least 1 month: delusions, hallucinations, disorganized speech, disorganized or catatonic behavior, and negative symptoms such as poor hygiene, blunted affect, and apathy. Additionally, there must be a significant decline in social or occupational functioning and continuous signs for at least 6 months.
First and second-generation antipsychotics are metabolized by CYP1A2, which can be induced by cigarette smoking, leading to increased metabolism of these medications in smokers. It is recommended that these medications be taken with a meal and preferably in the morning.
Haloperidol can cause side effects such as extrapyramidal symptoms (EPS), sedation, and anticholinergic effects. Monitoring is essential to manage these potential adverse effects.
Patients taking clozapine should be monitored for agranulocytosis, and regular blood tests are required to check white blood cell counts. They should also be informed about the risk of seizures and the need for adherence to the prescribed regimen.
'Heavy lungs' refers to the sedation and respiratory depression that can occur with certain antipsychotics, particularly those that are more sedating, such as haloperidol and loxapine.
Combining lorazepam with olanzapine can increase the risk of hypotension, respiratory depression, and central nervous system depression, making it a potentially dangerous combination.
If no improvement is observed within 2 weeks or only a partial decrease in positive symptoms is noted within 12 weeks, it may be necessary to consider the next treatment stage or switch to a different antipsychotic.
Key monitoring parameters include assessing for EPS, metabolic syndrome, sedation, and overall mental status. Regular follow-ups are essential to evaluate the effectiveness and side effects of the treatment.